BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

HHS Awards BioShield Contract For Botulism Antitoxin


6/1/2006 12:34:48 PM

WASHINGTON, June 1 /PRNewswire/ -- The Department of Health and Human Services (HHS) today awarded a contract to the Cangene Corporation of Winnipeg, Canada in the amount of $362,641,105 for 200,000 doses of Heptavalent Botulism Antitoxin. The contract runs for five years with product delivery to the Strategic National Stockpile scheduled to begin next year.

"Botulinum toxin is one of the most poisonous substances known to science," said Dr. Gerald Parker, HHS Acting Assistant Secretary for Public Health Emergency Preparedness. "Today's Project BioShield contract award is part of our effort to protect the American public from biological threats."

The number of doses being purchased under the new contract is based on the Department of Homeland Security's determination that botulinum toxins pose a threat to the U.S. population and the interagency Weapons of Mass Destruction Medical Countermeasures Subcommittee's recommendation that heptavalent botulism antitoxin be acquired to improve the nation's biodefense preparedness and response capabilities and protect civilians from a potentially lethal exposure to botulinum toxin.

The botulinum neurotoxin disrupts nerve functions which may result in muscle paralysis within hours. Respiratory muscle paralysis can result in death unless assisted (mechanical) ventilation is provided; therefore, the need for rapid diagnosis, access to intensive medical care, and antitoxin is vital. Botulism antitoxin blocks the action of circulating neurotoxin in the bloodstream.

HHS' Office of Public Health Emergency Preparedness, which oversees procurement efforts under the Project BioShield program through its Office of Research and Development Coordination, will manage the contract with Cangene.

Note: All HHS press releases, fact sheets and other press materials are available at http://www.hhs.gov/news.

U.S. Department of Health and Human Services

CONTACT: HHS Press Office, +1-202-690-6343



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES